Printer Friendly

Othera Pharmaceuticals Elects Hans Mueller to Board.

EXTON, Pa. -- Othera Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company developing proprietary drugs to treat or prevent the three leading causes of blindness, announced today that it has elected Hans Mueller, Ph.D. to its board of directors.

With a long career in the pharmaceutical industry dating back to 1969, Dr. Mueller most recently served as the Senior Vice President of Global Business Development for Wyeth Pharmaceuticals from 1993 to 2004.

"Dr. Mueller brings a wealth of large pharmaceutical company experience, particularly in the areas of strategy, licensing and collaboration to our drug development program as we anticipate having five phase 2 clinical trials underway in 2006," said David S. Joseph, Chairman and CEO of Othera. "His industry knowledge will aid our pursuit of ophthalmic pharmaceutical corporate alliances."

Dr. Mueller received his Ph.D. in Actuarial Science and Mathematical Statistics. He is a graduate of Harvard Business School's Advanced Management Program and a Lecturer at the University of Bern, Switzerland. His prior employment included Sandoz, now known as Novartis, and Nova Pharmaceuticals Inc., now known as Scios Inc. which is part of Johnson & Johnson.

About Othera

Othera Pharmaceuticals, Inc. is a privately-held, ophthalmic pharmaceutical company located in Exton, Pennsylvania. Othera is developing proprietary drugs to treat or prevent the three leading causes of blindness and vision impairment in the world - cataracts, age-related macular degeneration (AMD) and glaucoma. The Company's lead drug, OT-551, is a potent antioxidant eyedrop formulation to prevent the development of cataracts and AMD. Othera's novel beta-blocker drug, OT-730, is an eyedrop treatment for glaucoma. For information please visit our website at www.othera.com.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Othera Pharmaceuticals Elects Hans Mueller to Board.
Publication:Business Wire
Geographic Code:1USA
Date:Oct 12, 2005
Words:267
Previous Article:U.S. Department of Interior Expands FISMA Compliance Capabilities with Scalable Software.
Next Article:Great Wolf Resorts / CNL Income Properties Joint Venture Completes Purchase of Two Resorts.
Topics:


Related Articles
Agriculture Future of America (AFA).
NRC officers elected. (Municipal Recycling).
TAPPI Board of Directors slate announced.
MUELLER'S OFFENSE SPEAKS LOUDEST THIRD BASEMAN HELPS SPARK DODGERS TO VICTORY DODGERS 6, ARIZONA 4.
DODGERS: WHY NOT MOVE UP MUELLER? THIRD BASEMAN THRIVES NEAR BOTTOM.
DODGERS NOTEBOOK: MARTIN'S WEEKEND A HIT.
Akzo Nobel plans creation of two entities, Board changes.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters